The Multiple Myeloma pipeline report provides detailed information of the Multiple Myeloma pipeline products from the initial phase of product development until its commercialisation in the Multiple Myeloma market.

Multiple Myeloma Pipeline Drugs Insights Report

DelveInsight&rsquo;s, &ldquo;Multiple Myeloma Pipeline Insight, 2025,&rdquo; report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;
<h2>Geography Covered</h2>
<ul>
<li>Global coverage</li>
</ul>
<h2>Multiple Myeloma Understanding</h2>
Multiple Myeloma: Overview
Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal immunoglobulins. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: <a href="https://www.delveinsight.com/report-store/hyperkalemia-market">hypercalcemia</a>, renal dysfunction, <a href="https://www.delveinsight.com/report-store/anemia-market">anemia</a>, or bone pain accompanied by lytic lesions.&nbsp;
&nbsp;
Symptoms&nbsp;
The specific symptoms, age of onset, and rate of progression of multiple myeloma varies from patient to patient. Some affected individuals will not exhibit any symptoms (asymptomatic). Multiple myeloma may progress to cause life-threatening complications. The most common symptom associated with multiple myeloma is bone pain, usually of the lower back or ribs. Another possible sign of multiple myeloma is an elevated level of calcium in the blood, a condition called hypercalcemia.
&nbsp;
Causes
The exact cause of multiple myeloma is not known. Symptoms occur as a result of a process that is initiated by the abnormal multiplication of plasma cells in bone marrow. Scientists suspect there may be a variety of causes that may include environmental factors (e.g., the effects of exposure to radiation), genetic abnormalities, and/or additional factors that may play varying contributing roles. Exposure to dioxin has been associated with an increased risk of myeloma.
&nbsp;
Diagnosis
A diagnosis of multiple myeloma is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Such tests may include removal and microscopic examination of small samples of bone marrow (biopsy or aspiration), blood tests to detect low levels of red and white blood cells, and various x-ray techniques including <a href="https://www.delveinsight.com/report-store/magnetic-resonance-imaging-devices-market">magnetic resonance imaging</a> (MRI), <a href="https://www.delveinsight.com/report-store/computed-tomography-market">computed tomography</a> (CT), and <a href="https://www.delveinsight.com/report-store/positron-emission-tomography-market">positron emission tomography</a> (PET) scanning that may reveal characteristic changes to bones. A test that uses electric currents to sort proteins in the blood or urine (electrophoresis) may be used to detect elevated levels of M-proteins. An immunoglobulin free light chain assay of blood is considered a standard of evaluation.
&nbsp;
Treatment
The treatment of multiple myeloma usually involves chemotherapy to reduce the numbers of abnormal plasma cells, drugs to help fight infection (e.g., antibiotics), and medications to reduce pain (analgesic drugs). Additional treatment may include the use of high energy x-rays (radiation therapy) to destroy cancer cells and reduce bone masses that may develop. The use of new biologic drugs may also be recommended. If affected individuals experience involvement of the kidneys, fluids may need to be administered to avoid dehydration. Stem-cell transplantation along with high-dose chemotherapy is regularly used for the treatment of multiple myeloma.
💡 Stay Ahead in the Multiple Myeloma Market! Analyze growth trends, key players, and competitive landscapes. Get your copy of the market intelligence report now! @ <a href="https://www.delveinsight.com/report-store/multiple-myeloma-market">Multiple Myeloma Treatment Market</a>
"Multiple myeloma - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple myeloma pipeline landscape is provided which includes the disease overview and Multiple myeloma treatment guidelines. The assessment part of the report embraces, in depth Multiple myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
<h2>Report Highlights</h2>
<ul>
<li>The companies and academics are working to assess challenges and seek opportunities that could influence R&amp;D Multiple myeloma. The therapies under development are focused on novel approaches to treat/improve Multiple myeloma.</li>
</ul>
<h2>Multiple myeloma Emerging Drugs</h2>
Zevorcabtagene Autoleucel: Carsgen Therapeutics
Zevorcabtagene Autoleucel (Zevor-cel, R&amp;D code: CT053) is an autologous fully human <a href="https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape">CAR T-cell</a> product candidate against B-cell maturation antigen (BCMA) for the treatment of <a href="https://www.delveinsight.com/report-store/relapsed-refractory-multiple-myeloma-market">relapsed/refractory multiple myeloma</a> (R/R MM). In October 2022, China National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) and has granted the priority review for zevor-cel. Zevor-cel is expected to be approved by the NMPA for the treatment of R/R MM at the end of 2023 or the beginning of 2024. In January 2023, CARsgen and Huadong Medicine entered into a collaboration agreement for the commercialization of CARsgen's lead drug candidate, zevor-cel, in mainland China. Since reaching the agreement, teams from CARsgen and Huadong Medicine have been working together closely to implement this collaboration and prepare for the approval and commercialization of zevor-cel in China.
&nbsp;
Descartes 08: Cartesian Therapeutics
Descartes-08 is an autologous<a href="https://www.delveinsight.com/report-store/bcma-targeted-therapies-market-forecast"> BCMA</a>-targeting RNA-modified CAR T-cell therapy. Descartes-08 is engineered by mRNA transfection to express anti-BCMA CAR for a defined length of time. Descartes-08 express anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs. The magnitude of cytolysis correlates with anti-BCMA CAR expression duration, indicating a temporal limit in activity. In early-stage clinical studies, Descartes-08 has been safe and well-tolerated in patients with MG and multiple myeloma. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple Myeloma.
&nbsp;
GC012F: Gracell Biotechnology Shanghai Co., Ltd.
GC012F is Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and autoimmune disease treatment by driving fast, deep and durable responses with improved safety profile. GC012F is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune diseases, and has demonstrated a consistently strong efficacy and safety profile. Gracell has initiated a Phase 1b/2 trial evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in the United States and a Phase 1/2 clinical trial in China is to be commenced imminently.
&nbsp;
CID-103: CASI Pharmaceuticals&nbsp;
CID-103 is a fully human IgG1 <a href="https://www.delveinsight.com/report-store/anti-cd38-antibody-pipeline-insight">anti-CD38 monoclonal antibody</a> that recognizes a unique epitope on CD38. It was engineered to have strong activity against CD38 malignant cells and to reduce certain safety issues observed with existing treatments. Preclinical data of CID-103 demonstrates enhanced activity against a broad array of malignancies which express CD38 and demonstrates a better preclinical safety profile when compared to other CD38 mAbs. These attributes offer the potential for accelerated development and regulatory review, including rapid advancement into earlier lines of therapy. Currently, the drug is in the Phase I stage of its development for the treatment of Multiple Myeloma.
&nbsp;
STI-1492: Sorrento Therapeutics
STI-1492 is a therapeutic candidate developed by Sorrento Therapeutics for the treatment of relapsed or refractory multiple myeloma. It is an allogeneic, off-the-shelf therapy that involves the administration of Anti-CD38 A2 Dimeric Antigen Receptor T (DAR-T) cells through a single intravenous infusion. The therapy is currently being evaluated in a phase 1b, open-label, dose-escalation study involving subjects with relapsed or refractory multiple myeloma. <a href="https://www.delveinsight.com/report-store/cd38-market-forecast">CD38</a> is a transmembrane glycoprotein present on various immune cells and hematologic malignancies, and its expression has been associated with poor prognosis. Currently, the drug is in the Phase I stage of its development for the treatment of Multiple Myeloma.
📊 Data-Driven Decisions Start Here! Gain in-depth Multiple Myeloma epidemiological insights to drive research, drug development, and market strategies. Access the full report today! @ <a href="https://www.delveinsight.com/report-store/multiple-myeloma-epidemiology-forecast">Multiple Myeloma Prevalence</a>
<h2>Multiple myeloma: Therapeutic Assessment</h2>
This segment of the report provides insights about the Multiple myeloma drugs segregated based on following parameters that define the scope of the report, such as:
&nbsp;
Major Players in Multiple myeloma
There are approx. 75+ key companies which are developing the therapies Multiple myeloma. The companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e Registered include Carsgen Therapeutics.
&nbsp;
Phases
DelveInsight&rsquo;s report covers around 80+ products under different phases of clinical development like
<ul>
<li>Late stage products (Phase III)</li>
<li>Mid-stage products (Phase II)</li>
<li>Early-stage product (Phase I) along with the details of&nbsp;</li>
<li>Pre-clinical and Discovery stage candidates</li>
<li>Discontinued &amp; Inactive candidates</li>
</ul>
&nbsp;
Route of Administration
Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as&nbsp;
<ul>
<li>Oral</li>
<li>Intravenous</li>
<li>Subcutaneous</li>
<li>Parenteral&nbsp;</li>
<li>Topical</li>
</ul>
&nbsp;
Molecule Type
Products have been categorized under various Molecule types such as
<ul>
<li>Recombinant fusion proteins</li>
<li>Small molecule</li>
<li>Monoclonal antibody</li>
<li>Peptide</li>
<li>Polymer&nbsp;</li>
<li>Gene therapy</li>
</ul>
&nbsp;
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
<h2>Multiple Myeloma: Pipeline Development Activities</h2>
The report provides insights into different therapeutic candidates in phase III, II, I and preclinical stage. It also analyses Multiple Myeloma therapeutic drugs key players involved in developing key drugs.
&nbsp;
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple Myeloma drugs.
<h2>Multiple Myeloma Report Insights</h2>
<ul>
<li>Multiple Myeloma Pipeline Analysis</li>
<li>Therapeutic Assessment</li>
<li>Unmet Needs</li>
<li>Impact of Drugs</li>
</ul>
<h2>Multiple Myeloma Report Assessment</h2>
<ul>
<li>Pipeline Product Profiles</li>
<li>Therapeutic Assessment</li>
<li>Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
<h2>Key Questions</h2>
Current Treatment Scenario and Emerging Therapies:
<ul>
<li>How many companies are developing Multiple Myeloma drugs?</li>
<li>How many Multiple Myeloma drugs are developed by each company?</li>
<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple Myeloma?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Multiple Myeloma therapeutics?</li>
<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for Multiple Myeloma and their status?</li>
<li>What are the key designations that have been granted to the emerging drugs?</li>
</ul>
Related Articles By DelveInsight On Multiple Myeloma:
<ul>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/blog/high-risk-smoldering-multiple-myeloma">Understanding High Risk Smoldering Multiple Myeloma: A Bridge Between MGUS and Multiple Myeloma</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/blog/the-changing-landscape-of-multiple-myeloma-therapies-market">The changing landscape of Multiple Myeloma therapies market</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/blog/multiple-myeloma-market">Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/blog/competitive-analysis-of-celmods-and-revlimid">CELMoDs &ndash; A Worthy Successor to REVLIMID?</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/blog/multiple-myeloma-treatment">Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/blog/bispecific-antibodies-for-multiple-myeloma-treatment">A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/blog/cd38-directed-therapies-for-multiple-myeloma-treatment">Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/blog/bms-and-janssen-multiple-myeloma-treatment-drugs">BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/infographics/multiple-myeloma-market">Multiple Myeloma Market: Infographics</a></li>
<li><a style="color: #3598db;" href="https://www.delveinsight.com/whitepaper-newsletter/multiple-myeloma-newsletter">Multiple Myeloma Newsletter</a></li>
<li><a style="box-sizing: border-box; border: 0px solid #e5e7eb; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-scroll-snap-strictness: proximity; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; color: #3598db;" href="https://www.delveinsight.com/infographics/multiple-myeloma-market"><span style="box-sizing: border-box; border: 0px solid #e5e7eb; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-scroll-snap-strictness: proximity; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; font-weight: 600;">Multiple Myeloma Market: Infographic</a></li>
<li><a style="box-sizing: border-box; border: 0px solid #e5e7eb; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-scroll-snap-strictness: proximity; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; color: #3598db;" href="https://www.delveinsight.com/whitepaper-newsletter/multiple-myeloma-newsletter"><span style="box-sizing: border-box; border: 0px solid #e5e7eb; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-scroll-snap-strictness: proximity; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; font-weight: 600;">Multiple Myeloma Newsletter</a></li>
</ul>

Introduction
Executive Summary
Multiple myeloma: Overview
<ul>
<li>What is Multiple myeloma?</li>
<li>Types of Multiple myeloma</li>
<li>Causes</li>
<li>Epidemiology and Risk Factors</li>
<li>Disease Management</li>
</ul>
Pipeline Therapeutics
<ul>
<li>Comparative Analysis</li>
</ul>
Therapeutic Assessment
<ul>
<li>Assessment by Product Type</li>
<li>Assessment by Stage and Product Type</li>
<li>Assessment by Route of Administration</li>
<li>Assessment by Stage and Route of Administration</li>
<li>Assessment by Molecule Type</li>
<li>Assessment by Stage and Molecule Type</li>
</ul>
Multiple myeloma&ndash; DelveInsight&rsquo;s Analytical Perspective
Late Stage Products (Phase III)
<ul>
<li>Comparative Analysis</li>
</ul>
Venetoclax: AbbVie
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Mid Stage Products (Phase II)
<ul>
<li>Comparative Analysis</li>
</ul>
PHE885: Novartis
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Early Stage Products (Phase I/II)
ONC 201: Oncoceutics
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Early Stage Products (Phase I)
<ul>
<li>Comparative Analysis</li>
</ul>
TNB 383B: TeneoBio
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Inactive Products
<ul>
<li>Comparative Analysis</li>
</ul>
Multiple myeloma Key Companies
Multiple myeloma Key Products
Multiple myeloma- Unmet Needs
Multiple myeloma- Market Drivers and Barriers
Multiple myeloma- Future Perspectives and Conclusion
Multiple myeloma Analyst Views
Multiple myeloma Key Companies
Appendix

DelveInsight’s, “Multiple Myeloma Pipeline Insights, 2025,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Multiple Myeloma Pipeline

Multiple Myeloma (MM) - Pipeline Insight, 2025

Multiple Myeloma Pipeline Insights 2022 report by DelveInsight outlays comprehensive insights of present clinical development scenario & growth prospects across the Multiple Myeloma market